New research helps explain why a subset of patients with relapsing/remitting multiple sclerosis (MS) experience long-term ...

Sphingosine is a membrane component in all cells and constitutes 25% of the lipid in the myelin sheath. Sphingosine is phosphorylated by ubiquitously expressed sphingosine kinases. S1P regulates ...

uhbs.ch Objective The 12-month (M), phase 3, double-blind, randomised TRANSFORMS study demonstrated significant benefits of fingolimod 0.5 or 1.25 mg over interferon β-1a (IFNβ-1a) in patients with ...

The quest to understand and slow disease progression in multiple sclerosis (MS) continued in 2024, with research revealing ...

导读 2024年欧洲多发性硬化研究和治疗委员会大会（ECTRIMS ...

Fingolimod is associated with a 0.5–0.6% of macular edema, usually presenting within the first 3–4 months; diagnosis usually requires optical coherence tomography and/or fluorescein angiography.

Ponesimod, alemtuzumab, teriflunomide, ozanimod, and fingolimod significantly reduce brain volume loss compared with placebo. Indirect treatment comparisons reveal varying impacts of disease ...

PONVORY rose to the first choice position both in the 200 U.S. neurology study and the 400 multiple sclerosis patients study. The prescribers preferred ponesimod over siponimod, fingolimod and ...

The UK's National Institute for Clinical and Health Excellence has issued final draft guidance recommending the NHS to use Sanofi's Aubagio (teriflunomide) for adult patients with relapsing ...

Notably, this review thoroughly examines the role of traditional and emerging potential therapeutic medications for MASLD, including drugs targeting sphingolipid metabolism, such as Myriocin, ...

When it does launch, Zeposia will compete most closely with Novartis’ first-to-market S1P therapy Gilenya (fingolimod) – which made $3.2 billion in 2019 sales – and the Swiss drugmaker’s ...